Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Aurelie Abou Lovergne"'
Autor:
Lambros Tselikas, Eric Angevin, Antoine Hollebecque, Jean-Yves Scoazec, Francesco Facchinetti, Aline Maillard, Maud Ngo-Camus, C. Naltet, Ken A. Olaussen, Anas Gazzah, Stefan Michiels, Fabrice Andre, Thierry de Baere, Ludovic Bigot, David Planchard, Gilles Vassal, Ludovic Lacroix, Eric Solary, Catherine Richon, Luc Friboulet, Olivier Deas, Benjamin Besse, Linda Mahjoubi, Claudio Nicotra, Rastislav Bahleda, Yohann Loriot, Rosa L. Frias, Pernelle Lavaud, Aurelie Abou Lovergne, Gonzalo Recondo, Laura Mezquita, Christophe Massard, Jean-Charles Soria, Alexander M.M. Eggermont
Publikováno v:
NPJ Precision Oncology
npj Precision Oncology
npj Precision Oncology, Vol 4, Iss 1, Pp 1-8 (2020)
npj Precision Oncology
npj Precision Oncology, Vol 4, Iss 1, Pp 1-8 (2020)
Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c813a9e81b4b8bd223b9df16a7069df
https://pubmed.ncbi.nlm.nih.gov/32964129
https://pubmed.ncbi.nlm.nih.gov/32964129
Autor:
Jean-Yves Scoazec, Jean-Charles Soria, Gonzalo Recondo, Aurelie Abou Lovergne, Gilles Vassal, Tony Sourisseau, Pernelle Lavaud, Justine Galissant, Nathalie Auger, Antoine Hollebecque, Laura Mezquita, Alexander M.M. Eggermont, Maud Ngo-Camus, Karen Howarth, Christophe Massard, Rastilav Bahleda, David Planchard, Rosa L. Frias, Lambros Tselikas, Anas Gazzah, Fabrice Andre, Eric Angevin, Stefan Michiels, Floriane Braye, Luc Friboulet, Ken A. Olaussen, Ahsan Z. Rizvi, Linda Mahjoubi, Ludovic Bigot, Claudio Nicotra, Francesco Facchinetti, C. Naltet, Pauline Tesson, Ludovic Lacroix, D. O. Samofalova, Benjamin Besse, Eric Solary, Catherine Richon, Thierry de Baere, Jean Paul Thiery, Olivier Deas
Publikováno v:
Clin Cancer Res
Clinical Cancer Research
Clinical Cancer Research
Purpose:Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c9b635770828eacee7c1c495361e722
https://pubmed.ncbi.nlm.nih.gov/31585938
https://pubmed.ncbi.nlm.nih.gov/31585938
Autor:
Gonzalo Recondo, Laura Mezquita, David Planchard, Anas Gazzah, Francesco Facchinetti, Ludovic Bigot, Ahsan Z. Rizvi, Jean-Paul Thiery, Jean-Yves Scoazec, Rosa L. Frias, Tony Sourisseau, Linda Mahjoubi, Justine Galissant, Aurelie Abou-Lovergne, Gilles Vassal, Rastislav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngocamus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry De Baere, Frederic Deschamps, Eric Solary, Ken A. Olaussen, Eric Angevin, Alexander Eggermont, Fabrice André, Christophe Massard, Jean-Charles Soria, Benjamin Besse, Luc Friboulet
Publikováno v:
Cancer Research. 79:311-311
Background: ALK rearrangements occur in 3-6% of patients (pts) with lung adenocarcinoma. Lorlatinib, is a novel third generation ALK tyrosine kinase inhibitor (TKI) with proven efficacy for patients previously treated with second generation ALK TKI.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcbedc7654adf4fe163d57a4412d6afa
https://doi.org/10.1158/1538-7445.am2019-311
https://doi.org/10.1158/1538-7445.am2019-311